title: Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation.
abstract: OBJECTIVE
  We compared characteristics of schizophrenia patients with prior LSD use who developed hallucinogen persisting perception disorder (SCH+HPPD) with those who did not (SCH-HPPD).
  
  
  METHODS
  Data were collected for 37 subjects in the SCH+HPPD group and 43 subjects in the SCH-HPPD group.
  
  
  RESULTS
  Socio-demographics and positive symptom scores were similar between groups. Individuals in the SCHIZO+HPPD group scored lower on general psychopathology and negative symptoms scores.
  
  
  CONCLUSIONS
  Individuals with schizophrenia and HPPD present with less severe psychopathology, despite persistent perceptual disturbances.
  
  
  CONCLUSIONS
  Our findings highlight the importance of further research into this subset of patients.
authors: Addiction Medicine Services, Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.|Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Shaul
authors: S
authors: Lev-Ran
authors: Addiction Medicine Services, Department of Psychiatry, Sheba Medical Center, Tel Hashomer, Israel.|Department of Psychology, Ariel University, Israel.
authors: Daniel
authors: D
authors: Feingold
authors: Lev Hasharon Mental Health Center, Pardesya, Israel.
authors: Dmitri
authors: D
authors: Rudinski
authors: Lev Hasharon Mental Health Center, Pardesya, Israel.
authors: Stefan
authors: S
authors: Katz
authors: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.|Lev Hasharon Mental Health Center, Pardesya, Israel.
authors: Lerner G
authors: LG
authors: Arturo
mesh_terms: D000328:Adult; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D006212:Hallucinations / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D006213:Hallucinogens / Q000009:adverse effects*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000009:adverse effects*; D008297:Male; D010468:Perceptual Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D018570:Risk Assessment; D012559:Schizophrenia / Q000175:diagnosis / Q000453:epidemiology*; D012565:Schizophrenic Psychology; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D014796:Visual Perception / Q000187:drug effects*
chemical_list: D006213:Hallucinogens; D008238:Lysergic Acid Diethylamide